Genocea Biosciences is harnessing the power of T cell immunity to develop the next generation of vaccines.
T cells are increasingly recognized as a critical element of a protective immune response to a wide range of infectious disease pathogens, but are difficult to target using traditional vaccine discovery methods. Genocea is uniquely able to identify and employ T cell antigens using ATLAS, its proprietary technology platform, which mimics human T cell immune response in the laboratory, potentially improving the effectiveness of vaccine candidates and drastically reducing the time needed to create them. Genocea’s pipeline of novel T cell vaccines includes a clinical-stage program in Herpes Simplex Virus type 2 (HSV-2) therapy, as well as earlier-stage programs in Pneumococcus, Chlamydia, HSV-2 prophylaxis and malaria.
The density of the Boston biotech cluster offers many options to biotech start-ups, but this poses challenges. Being part of the Polaris family means being able to navigate the cluster better. It means being able to find the RIGHT potential partners, the RIGHT scientific advisor, the RIGHT law firm for your company's needs. Offering this, on top of the battle-tested strategic counsel, makes Polaris a terrific partner.
- Chip Clark, CEO : Genocea